Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
MWN-AI** Summary
Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced plans to release its financial results for the fourth quarter and full year of 2025 on March 17, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide updates on their corporate progress. Participants can join the call by dialing in or accessing it via webcast, with a replay available for 30 days afterwards on the company's investor relations website.
In addition to their financial results announcement, Abeona management will take part in the 2026 Leerink Global Healthcare Conference on March 10, 2026. They will engage in a fireside chat at 8:40 a.m. ET, which can also be accessed live through a webcast, with the option to view the recorded session for 30 days.
Abeona Therapeutics is a biopharmaceutical company focusing on developing innovative cell and gene therapies for serious diseases, notably their product ZEVASKYN® (prademagene zamikeracel), the first autologous cell-based gene therapy designed to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company operates a cGMP manufacturing facility in Cleveland, Ohio, which supports ZEVASKYN's commercial production. In addition to ZEVASKYN, Abeona is advancing a portfolio of adeno-associated virus (AAV)-based gene therapies aimed at addressing unmet needs in treating ophthalmic diseases.
The announcement also includes forward-looking statements that highlight potential risks and uncertainties affecting the company. Factors that could impact results include the commercialization of ZEVASKYN, regulatory approvals, and broader market conditions.
For further details, interested parties can visit Abeona Therapeutics' official website.
MWN-AI** Analysis
Abeona Therapeutics Inc. (Nasdaq: ABEO) has scheduled an important conference call for March 17, 2026, to discuss its financial results for Q4 and the full year of 2025. This event, in conjunction with its participation in the upcoming Leerink Global Healthcare Conference on March 10, 2026, presents a noteworthy opportunity for investors to gauge the company’s progress and market outlook.
Given Abeona’s focus on innovative gene and cell therapies, particularly with its product ZEVASKYN® for treating recessive dystrophic epidermolysis bullosa, the investor community will be keen to assess its commercialization strategies and market penetration. The company's proactive effort in hosting discussions around their financial health and corporate advancements indicates transparency, which can help restore or bolster investor confidence.
For potential investors, monitoring the developments in key areas such as ZEVASKYN’s manufacturing capabilities and regulatory approvals will be critical. Despite the positive momentum, investors should remain aware of the inherent risks, including the company’s ability to meet manufacturing demands and obtain necessary regulatory clearances for its pipeline programs.
Furthermore, with the healthcare sector's continual evolution, Abeona's strategic position within the high-demand areas of rare and serious diseases suggests a potential for growth. However, caution is warranted. Investors should analyze Abeona’s financial results in detail during the upcoming call, focusing on revenue performance, cost management, and future guidance.
In summary, while Abeona Therapeutics demonstrates promise through its innovative product portfolio, due diligence in assessing financial outcomes and broader market conditions is imperative for informed investment decisions. Continuous monitoring of their forthcoming announcements and regulatory feedback will further clarify Abeona's trajectory in the dynamic biopharmaceutical landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.
The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the call.
Participation in 2026 Leerink Global Healthcare Conference
Abeona management will participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 a.m. Eastern Time. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts:Investor and MediaGreg GinVP, Investor Relations and Corporate CommunicationsAbeona Therapeuticsir@abeonatherapeutics.comInvestorLee M. SternMeru Advisorslstern@meruadvisors.com
FAQ**
How does Abeona Therapeutics Inc. (ABEO) plan to address the manufacturing challenges for ZEVASKYN to meet market demand, particularly given the risks mentioned in the press release?
What specific milestones can investors expect Abeona Therapeutics Inc. (ABEO) to achieve in the development of its AAV-based gene therapies for ophthalmic diseases in the upcoming year?
How does Abeona Therapeutics Inc. (ABEO) measure the therapeutic potential and market opportunity of ZEVASKYN, especially in relation to the unmet needs identified in their target patient population?
Can you provide insights on the company's strategy for enrolling patients in clinical trials and how Abeona Therapeutics Inc. (ABEO) is addressing potential obstacles that could impact trial outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Abeona Therapeutics Inc. (NASDAQ: ABEO).
NASDAQ: ABEO
ABEO Trading
0.73% G/L:
$4.81 Last:
435,056 Volume:
$4.77 Open:
